Table S1: Characteristics and outcome of patients as randomized during consolidation with 2CDA versus AI
2-CDA
AI
2-CDA
AI
p-value (
N
N
EFS 5 year (SE)
Number of patients
168
175
53 (4)
49 (4)
Age (years) median
5.4
6.2
0.80
(Q1-Q3)
1.6-12.9
1.4-13.7
Leukocytes (x10³/µl)
23,350
12,600
0.10
median
(Q1-Q3)
4,785-81,450
4,200-58,300
%
%
N
N
p-value (
Gender
0.42
Male
84
50
94
54
50.8 (6)
52.5 (5)
Female
84
50
81
46
54.0 (6)
45.1 (6)
CNS
18/166
11
29/171
17
0.11
59.0 (12)
47.3 (9)
involvement*;**
Extramedullary
organ involvement
FAB
M4
M5
Other
Cytogenetic data
available*
36
21
44
25
32
48
120
19
29
71
35
48
127
20
27
73
156/168
93
154/175
97
0.40
p-value
(logrank
0.77
0.80
0.42
0.43
58.2 (8)
60.7 (8)
0.85
38.1 (9)
64.5 (7)
51.2 (5)
44.5 (9)
56.2 (7)
47.0 (5)
0.65
0.69
0.56
0.96
0.64
t(8;21)
9
6
9
6
inv(16)
1
1
2
1
Normal
35
22
41
27
51(9)
45(8)
MLL
50
32
54
35
55.9 (7)
55.6 (7)
Other
61
39
48
31
48(7)
47(7)
Blasts day 15 >5%*
37/153
24
36/162
22
0.68
27.0 (7)
35.7 (8)
*Percentage is given for patients with data (n/total)
**There was no difference in survival, event-free survival and cumulative incidence of relapse in CNS positive or negative patients.
Abbreviation: Q, quartil
0.54
0.73
0.94
0.40